ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced the election of Laura A. Brege to its board of
directors. Ms. Brege will fill a vacancy on the Board and serve as a
Class III director. The terms of the Class III directors expire at the
annual meeting of stockholders in 2010.
“We are delighted that Laura Brege has joined
ACADIA’s board,”
said Uli Hacksell, Ph.D., Chief Executive Officer of ACADIA. “Her
strong blend of financial, operational, and industry experience will be
a valuable asset as we continue to advance our pipeline of drug
candidates and position them for commercial success.”
Ms. Brege is Executive Vice President and Chief Operating Officer of
Onyx Pharmaceuticals, Inc. where she is responsible for sales and
marketing, medical affairs, legal, business development, and compliance
functions. She joined Onyx in June 2006 as Executive Vice President and
Chief Business Officer and was promoted to her current position in
October 2007. Before joining Onyx, Ms. Brege was a general partner at
Red Rock Management, a venture capital firm. Prior to Red Rock, she was
Senior Vice President and Chief Financial Officer at COR Therapeutics.
Earlier in her career, Ms. Brege served as Vice President and Chief
Financial Officer at Flextronics and Vice President and Treasurer of The
Cooper Companies. Ms. Brege earned her undergraduate degree from Ohio
University and has an M.B.A. from the University of Chicago. Ms. Brege
also serves on the boards of Angiotech Pharmaceuticals, Inc. and The
Ohio University Foundation.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovative technology to
fuel drug discovery and clinical development of novel treatments for
central nervous system disorders. ACADIA currently has five mid-to-late
stage clinical programs as well as a portfolio of preclinical and
discovery assets directed at diseases with large unmet medical needs,
including schizophrenia, Parkinson’s disease
psychosis, sleep maintenance insomnia, and neuropathic pain. All of the
drug candidates in ACADIA’s product pipeline
emanate from discoveries made using its proprietary drug discovery
platform. ACADIA’s corporate headquarters is
located in San Diego, California and it maintains research and
development operations in both San Diego and Malmö,
Sweden.
Forward-Looking Statements
Statements in this press release that are not strictly historical in
nature are forward-looking statements. These statements include but are
not limited to statements related to the potential benefits from this
appointment to ACADIA’s pipeline of drug
candidates or their commercial success. These statements are only
predictions based on current information and expectations and involve a
number of risks and uncertainties. Actual events or results may differ
materially from those projected in any of such statements due to various
factors, including the risks and uncertainties inherent in drug
discovery, development and commercialization, and the fact that past
results of clinical trials may not be indicative of future trial
results. For a discussion of these and other factors, please refer to
ACADIA’s annual report on Form 10-K for the
year ended December 31, 2007 as well as ACADIA’s
subsequent filings with the Securities and Exchange Commission. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. This caution is made
under the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. All forward-looking statements are qualified in
their entirety by this cautionary statement and ACADIA undertakes no
obligation to revise or update this press release to reflect events or
circumstances after the date hereof.
|